Matrix metalloproteinase-1 is a crucial bone metastasis factor in a human breast cancer-derived highly invasive cell line

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1497-1504

  Okuyama, Noritaka ^a   Matsumine, Akihiko ^a   Kosugi, Rieko ^a   Wakabayashi, Hiroki ^a   Uchica, Atsumasa ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metastasis; Breast cancer; In vitro selection system; Invasion; Matrix metalloproteinase 1

Indexed keywords

COLLAGENASE 3; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 5; STROMELYSIN; UNCLASSIFIED DRUG; COLLAGEN; LAMININ; MATRIGEL; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY; ANIMAL; BONE TUMOR; BREAST TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; DRUG COMBINATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; TIME; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; MATRIX METALLOPROTEINASE 1; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 59249086543     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000171     Document Type: Article

References (42)

1. Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987.
2. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of Letrozole versus Tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of phase III study of the international Letrozole breast cancer group. J Clin Oncol 19: 2596-2606, 2001.
3. Mastro LD, Venturini M, Lionetto R, et al: Accelerated-intensified cyclophosphamide, epirubicin and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian gruppo oncologico Nord-Ouest-Mammella inter gruppo group. J Clin Oncol 19: 2213-2221, 2001.
4. Cailleau R, Yong R, Olive M and Reeves W: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661-674, 1974.
5. Yoneda T, Sasaki A and Mundy GR: Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32: 73-84, 1994.
6. Fidler IJ: Selection of successive tumor lines for metastasis. Nature New Biol 242: 148-149, 1973.
7. Fidler IJ, Gersten DM and Budmen MB: Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res 36: 3160-3165, 1976.
8. Briles EB and Kornfeld S: Isolation and metastatic properties of detachment variants of B16 melanoma cells. J Natl Cancer Inst 60: 1217-1222, 1978.
9. Kerbel RS, Twiddy RR and Robertson DM: Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Int J Cancer 22: 583-594, 1978.
10. Suzuki N and Withers HR: Lung colony formation: a selective cloning progress for lung-colony-forming ability. Br J Cancer 39: 196-199, 1979.
11. Poste G, Doll J, Hart IR and Fidler IJ: In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 40: 1636-1644, 1980.
12. Albercht-Bueler G: The phagokinetic track assay of 3T3 cells. Cell 11: 395-404, 1977.
13. Seyedin SM, Thompson AY, Bentz H, et al: Cartilage-inducing factor-A. J Biol Chem 261: 5693-5695, 1986.
14. Guise TA: Molecular mechanisms of osteolytic bone metastases. Cancer 88: 2892-2898, 2000.
15. Pfeilschifter J and Mundy G: Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 84: 2024-2028, 1987.
16. Lin M and Golen KL: Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 84: 49-60, 2004.
17. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
18. Duffy MJ, Maguire TM, Hill A, McDermott E and O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252-257, 2000.
19. John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7: 14-23, 2001.
20. Sternlicht MD and Werb Z: How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 17: 463-516, 2001.
21. Stetler-Stevenson WG and Yu AE: Proteinases in invasion: matrix metalloproteinases. Semin Cancer Biol 11: 143-152, 2001.
22. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
23. Lochter A and Bissell M: An odyssey from breast to bone: Multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 107: 128-136, 1999.
24. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD and Okada Y: Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. J Biochem 322: 809-814, 1997.
25. English WR, Puente XS, Freije JMP, et al: Membrane Type 4 matrix metalloproteinase (MMP-17) has tumor necrosis factor-α convertase activity but does not activate pro-MMP2. J Biol Chem 275: 14046-14055, 2000.
26. Kang Y, Siegel PM, Shu W, et al: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549, 2003.
27. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N and Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87: 602-611, 1996.
28. Brummer O, Athar S, Riethdorf L, Loning T and Herbst H: Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 435: 566-573, 1999.
29. Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM and Duffy MJ: Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77: 926-931, 1988.
30. Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A and Davaris P: Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 30: 436-442, 1999.
31. Lhotak S, Elavathil LJ, Vukmirovic-Popovic S, Duivenvoorden WCM, Tozer RG and Singh G: Immuno-localization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clin Exp Metastasis 18: 463-470, 2001.
32. Mackie EJ: Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol 35: 1301-1305, 2003.
33. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW and Martin GR: Basement membrane complexes with biological activity. Biochemistry 25: 312-318, 1986.
34. Kawamata H, Furihata T, Omotehara F, et al: Identification of genes differentially expressed in a newly isolated human metastasizing esophageal cancer cell line, T.Tn-AT1, by cDNA microarray. Cancer Sci 94: 699-706, 2003.
35. Farina AR, Tacconelli A, Cappabianca L, Gulino A and Mackay AR: Inhibition of human MDA-MB-231 breast cancer cell invasion by matrix metalloproteinase 3 involves degradation of plasminogen. Eur J Biochem 269: 4476-4483, 2002.
36. Eilon G and Mundy GR: Direct resorption of bone by human breast cancer cells in vitro. Nature 276: 726-728, 1978.
37. Nemth JA, Yousif R, Herzog M, et al: Matrix metalloproteinase activity, bone matrix turnover and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94: 17-25, 2002.
38. Pederson L, Winding B, Foged NT, Spelsberg TC and Oursler MJ: Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 59: 5849-5855, 1999.
39. Tumber A, Morgan HM, Meikle MC and Hill PA: Human breastcancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants. Int J Cancer 91: 665-672, 2001.
40. Powell GJ, Southby J, Danks JA, et al: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51: 3059-3061, 1991.
41. Gallwitz WE, Guise TA and Mundy GR: Guanosine nucleotides inhibit different syndromes of PTH-rP excess caused by human cancers in vivo. J Clin Invest 110: 1559-1572, 2002.
42. Sanchez-Sweatman OH, Lee J, Orr FW and Singh G: Directly osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer 33: 918-925, 1997.